|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University of Chile |
| Information provided by: | University of Chile |
| ClinicalTrials.gov Identifier: | NCT00276952 |
Purpose
The purpose of this study is to evaluate the clinical efficacy of Gonyautoxin 2/3 epimers in the treatment of patients diagnosed with chronic tensional-type headache in accordance with International Headache Society guidelines
| Condition | Intervention | Phase |
|
Tension-Type Headache |
Drug: Gonyautoxin |
Phase II |
| MedlinePlus related topics: | Headache |
| ChemIDplus related topics: | Gonyautoxin |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Phase 2 Study of Treatment of Chronic Tension-Type Headache Using Gonyautoxins |
| Estimated Enrollment: | 27 |
| Study Start Date: | September 2004 |
| Estimated Study Completion Date: | August 2005 |
Gonyautoxin are phycotoxins, whose molecular mechanism of action is a reversible block of the voltage-gated sodium channels at neuronal level. They are axonal conduction blockers impeding nerve impulse propagation. In order to evaluate the clinical efficacy of Gonyautoxin 2/3 epimers in the treatment of patients diagnosed with chronic tensional-type headache, the patients were locally injected with placebo versus Gonyautoxin following a painful spots injection standarized protocol
Eligibility
| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Chile | |||||
| Departament of Neurology and Neurosurgery, Hospital Clínico Universidad de Chile. | |||||
| Santiago, Chile, 0 | |||||
| University of Chile |
| Principal Investigator: | Nestor Lagos, PhD | Faculty of Medicine University of Chile |
More Information
| Study ID Numbers: | HCUCH-NL-GTX-002 |
| First Received: | January 12, 2006 |
| Last Updated: | January 12, 2006 |
| ClinicalTrials.gov Identifier: | NCT00276952 |
| Health Authority: | Chile: Instituto de Salud Publica de Chile |
|
|
|
|